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Visual Impairment/Intracranial Pressure (VIIP) is a top human
spaceflight risk for which NASA does not currently have a proven
mitigation strategy. Thigh cuffs and lower body negative pressure
(LBNP) devices have been or are currently being evaluated as a
means to reduce VIIP signs and symptoms, but these methods
alone may not provide sufficient relief of cephalic venous
congestion and VIIP symptoms. Additionally, current LBNP
devices are too large and cumbersome for their systematic use as
a countermeasure. Therefore, a novel approach is needed that is
easy to implement and provides specific relief of symptoms. This
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Pilot data demonstrate substantial reductions in IJV cross
sectional area and in estimated ICP as measured by CCFP. Human
subject testing is planned for February 2017.
The investigation team recognizes that ITD use as a routine
countermeasure during spaceflight may not be particularly
comfortable in its current form and function. The purpose of the
planned work is to 1) use the ITD as a tool to further understand
VIIP, and 2) establish the effectiveness of this methodology before
embarking on more in-depth investigations to develop and validate
a countermeasure with optimized crewmember acceptability.
The ITD provides up to 7 cm H2O (~5 mmHg) resistance to
inspiratory air flow, which upon each inhalation effectively turns
the thorax into a vacuum pump that lowers the intrathoracic
pressure (ITP) to facilitate venous return to the heart. The ITD is
FDA-approved and was developed to augment venous return to
the heart and increase cardiac output in patients with
hypotension and during cardiopulmonary resuscitation (CPR).
While the effect of ITD on CPR survival outcomes is controversial,
it’s ability to lower ITP with a concomitant decrease in intracranial
pressure (ICP) is well documented1. A similar concept that creates
negative ITP during exhalation (intrathoracic pressure regulator;
ITPR) decreased ICP in 16 of 20 patients with elevated ICP in a
hospital pilot study2. ITP and central venous pressure (CVP) have
been shown to decrease in microgravity3,4. However ITP drops
more than CVP, indicating an increased transmural CVP. This
could explain the paradoxical distention of jugular veins (JV) in
microgravity despite lower absolute CVP and also suggests that
JV transmural pressure is not dramatically elevated. Use of an ITD
may lower JV pressure enough to remove or relieve cephalic
venous congestion.
During spaceflight experiments Braslet thigh cuffs reduced
cardiac preload but only reduced the internal JV (IJV) cross
sectional area by 23%. The addition of modified (open-glottis)
Mueller maneuvers resulted in an IJV area reduction of 48%5. This
project will test the ITD’s ability to lower ITP in each respiratory
cycle, acting to: 1) reduce venous congestion in the head and
neck and 2) reduce ICP based on noninvasive indicators. The
expected mechanism of action for relief of venous congestion is
that in microgravity (or an analog), blood is relocated toward the
heart from vasculature in the head and neck. Reduction of ICP
would occur as a result of reduced ITP1.
Once validated, the ITD would be an exceptionally easy
countermeasure to deploy and test on the ISS. Dosage could be
altered through 1) duration of application and 2) inspiratory
resistance set point. Effects could be additionally enhanced
through co-application with other countermeasures such as thigh
cuffs or LBNP.
SPECIFIC AIMS
Using a supine and head down tilt (HDT) model, this 
investigation will:
1. Determine if an ITD can reduce venous 
congestion in the head and neck
2. Determine if an ITD can reduce indicators of 
elevated intracranial pressure
Figure 1: ITD and face mask;
military kit shown incorporates
three exhalation vents for
minimized exhalation back
pressure and maximum subject
comfort.
Figure 2: Effect of ITD
breathing on ITP and
ICP in a porcine model
(from Convertino et al.) 1
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The experimental approach is to use a battery of tests that are
currently being used to evaluate the effects of other interventions.
Healthy test subjects (n=15) will participate in two sessions, one
with an ITD and one with a sham ITD (placebo). Subjects will be
evaluated in the seated and supine positions as well as 6º and 15º
HDT postures. Measures taken at each posture will include IJV
cross sectional area, carotid artery Doppler, measures of cardiac
preload, transcranial Doppler (TCD), optic nerve sheath diameter
(ONSD), superior ophthalmic vein (SOV) Doppler, facial soft tissue
thickness, IJV pressure (VeinPress), optical coherence
tomography (OCT), cochlear and cerebral fluid pressure analysis
(CCFP), otoacoustic emissions (OAE), and intraocular pressure
(IOP). Blood pressure, ECG, heart rate, and transcutaneous PCO2
and PO2 will be monitored throughout the experiment. Blood
samples will be drawn and archived for potential one carbon
pathway analysis.
PILOT RESULTS
Figure 3: Effect of ITD breathing on IJV
cross-sectional area in the supine
position. A: M-mode across the IJV
without ITD, B: B-mode (2D) image of the
IJV without ITD, C: M-mode across the IJV
with ITD, D: B-mode image of the IJV
without ITD. In panels A and C ECG is the
green trace and respiration in red.
Figure 5: Noninvasive indication
of ICP changes in response to
ITD breathing at different
postures. Tympanic Membrane
Displacement (TMD) values in
n=2 trials each panel. A: subjects
at 15° head up tilt (15HUT),
Supine, 15° head down tilt
(15HDT), and Supine with ITD
breathing (Supine+ITD). B:
subjects at 30° head up tilt
(30HUT), Supine, 15° head down
tilt (15HDT), and 15° head down




Figure 4: Effect of ITD
breathing on IJV time-
weighted cross sectional
area in different postures
(n=1). IJV cross sectional
area was time-averaged
over one full respiratory
cycle at 15° head up tilt
(15HUT), Supine, and 15°
head down tilt (15HDT),
each posture with and
without ITD breathing.
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